There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .
Infant formula composition affects energetic efficiency for growth: the BeMIM study, a randomized controlled trial.
BACKGROUND & AIMS Protein source , macronutrient composition and content of long chain-polyunsaturated fatty acids ( LC-PUFA ) of infant formulae may influence infant growth . We aim ed to assess the effect of a modified infant formula on growth . METHODS In a r and omized , double-blind trial , 213 healthy term infants consumed  isoenergetic study formulae ( intervention formula - IF , control formula - CF ) from the first month of life until the age of 120 days . IF ( 1.89 g protein/100 kcal ) contained α-lactalbumin ( ALAB ) and LC-PUFA , while CF ( 2.30 g protein/100 kcal ) provided st and ard whey and no LC-PUFA . Anthropometry and dietary intake were regularly assessed . A venous blood sample was obtained on day 120 . RESULTS Both formulae were well-accepted without significant differences in health related observations . Weight gain was not statistically different between formula groups ( IF : 30.2 ± 6.3 vs. CF : 28.3 ± 6.5 g/day , mean ± SD , P = 0.06 ) . Length gain was higher in IF ( 0.11 ± 0.02 vs. 0.10 ± 0.02 cm/day , P = 0.02 ) . Energy intake from formula was higher in CF at 90 and 120 days ( IF : 509 ± 117 and 528 ± 123 vs. CF : 569 ± 152 and 617 ± 169 kcal/day , P < 0.01 ) . Protein intake in CF was significantly higher at each assessment . Growth per energy intake was higher in IF compared to CF for weight ( 6.45 ± 2.01 vs. 5.67 ± 2.21 g/100 kcal , P = 0.02 ) and length ( 0.23 ± 0.08 vs. 0.20 ± 0.08 mm/100 kcal , P = 0.04 ) . CONCLUSIONS The modified infant formula with reduced protein content with added ALAB and LC-PUFA , meets infant requirements of protein for adequate growth . The increased energetic efficiency of the new infant formula might result from improved protein composition by added ALAB . Apparently minor differences in composition can markedly affect energetic efficiency for growth . The study was registered at Clinical Trials.gov ( NCT01094080 )
There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .